Amgen Inc
XMUN:AMG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Amgen Inc
XMUN:AMG
|
US |
|
M
|
MPC Container Ships ASA
SWB:MP2
|
NO |
|
Gubra A/S
F:PI3
|
DK |
|
Growthpoint Properties Australia Ltd
OTC:GRWPF
|
AU |
|
Ubisoft Entertainment SA
PAR:UBI
|
FR |
|
Atoss Software AG
F:AOF
|
DE |
Earnings Calls
Last Earnings Call
Strong quarter: Amgen said second-quarter revenue topped $10 billion, up 10% year over year, with broad-based strength across its portfolio and no sign of slowing demand.
Growth drivers: The company highlighted six key growth drivers that together rose 26% year over year and made up about 70% of product sales.
Guidance raised: Management lifted full-year 2026 revenue and earnings guidance and said it still expects strong margins while increasing investment in R&D and commercial growth.
Pipeline breadth: Amgen emphasized progress in MariTide, Olpasiran, Xaluritamig, UPLIZNA, TEZSPIRE and IMDELLTRA, alongside continued investment in AI and manufacturing.
Capital discipline: The company generated $3.5 billion in free cash flow, kept capex plans at about $2.6 billion for 2026, and signaled continued but disciplined business development and share repurchases.